About SymKardia
SymKardia is developing a new therapy for cardiac arrhythmias. The approach is selective cardiac neuromodulation, and the therapy is meant for patients with arrhythmias. The company is recruiting people with cardiovascular medical device development expertise to join its work.
The company is based in Westlake, Ohio. Bruce KenKnight is chief executive officer, and Imad Libbus is chief scientific officer. Dwight Skinner leads product development, quality assurance and operations. The team page also lists Steven Girouard, a medical device executive who is a board director, and Jonathan Piccini, a cardiac electrophysiologist at Duke University.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Jan 10, 2025 | Oct 28, 2026 | $4,000,000fully sold | 8 | $500K | Debt, Convertible notes and equity issuable upon any conversion thereofRule 506(b) | Form D ↗ |
| Jun 8, 2026 | Jun 18, 2026amended Oct 28, 2026 | $4,300,000of $12.0M target | 3 | $1.4M | Debt, Convertible notes and equity issuable upon any conversion thereofRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $8,300,000 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Why Investors Backed SymKardia
SymKardia is developing a cardiac neuromodulation therapy for patients with arrhythmias. Its stated mission is to improve how arrhythmias are treated. Its leaders have worked at LivaNova, Boston Scientific, Guidant, Medtronic and Valtech Cardio. The company is based in Westlake, Ohio.
The problem it targets
SymKardia's view is that approved arrhythmia therapies act only on cardiac tissue. The company believes selective cardiac neuromodulation can change how arrhythmias are treated and improve patient outcomes. That is the company's belief about its own approach.
Progress so far
SymKardia runs a pre-clinical and clinical research program, and chief scientific officer Imad Libbus is responsible for it. The company is looking for people with cardiovascular medical device development expertise to join its effort.
Who backs it
SymKardia has not named its investors on its site. Its chief executive officer, Bruce KenKnight, was a vice president at LivaNova and at Boston Scientific, and president and chief executive officer of Valtech Cardio. Libbus was R&D Fellow at LivaNova, senior director at Corventis and principal research scientist at Boston Scientific. Steven Girouard was president and chief executive officer of Securus Medical, which Boston Scientific acquired. Jonathan Piccini is a professor of medicine at Duke University and directs cardiac electrophysiology at the Duke Heart Center.
We wrote this summary from public statements by SymKardia and its investors. It is not investment advice.
Leadership Team
Executive officers and directors listed on SymKardia's Form D filed Oct 28, 2026.
